A 57-year-old man with a history of HIV disease, hyperlipidemia, and major depressive disorder presented to his primary care physician with depression and insomnia. His mood had been controlled with bupropion, 300 mg/d, for the past several years; however, the recent death of his husband led to increased hopelessness, insomnia, and decreased energy. Results of laboratory studies (thyroid-stimulating hormone, complete blood cell count, and metabolic profile) were unremarkable. His total score on the Patient Health Questionnaire 9 (PHQ-9) was 16 ( Table 1) . Answer C. The patient has depressive symptoms of at least moderate severity.
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The PHQ-9 is a self-report form based on symptoms experienced over the past 2 weeks that consists of 9 items (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), which are summed to yield a score ranging from 0 through 27. Scores of 5-9 represent mild depressive symptoms; 10-14, moderate; 15-19, moderately severe; and 20 or more, severe depressive symptoms. 2 A 3-to 5-point change in PHQ-9 score is clinically meaningful. 2 In primary care settings, a total score of 10 or higher has an estimated sensitivity of 81.3% (95% CI, 71.6%-89.3%), specificity of 85.3% (95% CI, 81.0%-89.1%), positive predictive value (PPV) of 44.2% (95% CI, 41.9%-46.6%), and positive likelihood ratio (LR+) of 6.9 (95% CI, 6.4-7.4) for major depressive disorder (MDD). 3 A higher threshold score (PHQ-9 score Ն14) has a lower sensitivity (56.0%) but higher specificity (96.6%), PPV (73.4%), and LR+ (16.5). 3 Advantages of the publicly accessible PHQ-9 include its self-report format, rapid scoring and interpretation, availability in multiple languages, suitability for remote administration (eg, via telehealth), and sensitivity to treatment-associated change. 2 
Application of Test Results to This Patient
This patient's PHQ-9 score indicates depressive symptoms of at least moderate severity. His symptoms, previously in remission, were likely exacerbated by the recent death of his husband. In addition, his history supports (but does not confirm) a diagnosis of MDD; patients with dysthymic disorder or subthreshold depression would typically have PHQ-9 scores lower than 16. Because the PHQ-9 does not screen for bipolar disorder, elevated PHQ-9 scores should prompt additional questions to exclude bipolar depression, including asking about a sustained period of grandiosity, decreased need for sleep, or pressured speech. Importantly, the patient was screened for and denied suicidal ideation (item 9, Table 1 ). For patients with a positive response for item 9, the P4 screener asks 4 questions (regarding suicidal past history, plan, probability, and preventive factors) that stratify patients into "minimal," "lower," and "higher" suicide risk levels. 4 Because anxiety co-exists in 30% to 50% of depressed patients, screening for anxiety with a measure such as the generalized anxiety disorder 7-item (GAD-7) scale is also reasonable.
2 Additionally, inquiry about alcohol and other substance use disorders is warranted. When screening for depression in patients with physical illness, concern has been raised about whether the 4 somati-
HOW WOULD YOU INTERPRET THESE TEST RESULTS?
A. The patient has major depressive disorder.
B.
The patient has dysthymic disorder.
C. The patient has depressive symptoms of at least moderate severity.
D.
The patient does not have bipolar disorder. cally focused items (fatigue, weight/appetite changes, sleep disturbance, and psychomotor symptoms) are specific to MDD. However, a study of 235 patients with diabetes or cardiopulmonary disease and 204 without these conditions found that only fatigue was significantly more common in patients with physical illness and that all 4 somatic symptoms showed similar improvement with depression treatment in patients with and without comorbidity.
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What Are Alternative Diagnostic Testing Approaches?
Many guidelines, including those of the US Preventive Services Task Force, 6 recommend routine screening for depression among adults and reference the PHQ-9 as one of the preferred instruments. The US Preventive Services Task Force also recommends the Geriatric Depression Scale, Edinburgh Postnatal Depression Scale, and Hospital Anxiety and Depression Scale, which are specific to defined populations ofpatients(Table2).ThePHQ-9isalsovalidatedfordepressionscreen-ing in older adults. 9 Multiple depression scales exist, and a conversion tool has been developed to cross-calibrate scores between the PHQ-9 and other scales. 10 Instead of using a screening tool, clinicians may interview patients for DSM-5 symptoms of MDD during history-taking. However, this unstructured assessment typically requires more time, and the 9 symptoms of MDD are measured by the PHQ-9 items. A PHQ-9 score of 10 or higher should prompt a more thorough evaluation, which is required to establish a diagnosis of MDD. 10 
Patient Outcome
The patient was referred to a psychiatrist. Bupropion was increased to 450 mg/d and his symptoms improved. Approximately a year later, his PHQ-9 score had decreased to 4.
Clinical Bottom Line
• Depression is common in primary care settings.
• The PHQ-9 is a short, publicly available, self-report form that screens for and tracks clinically significant depressive symptoms.
• Patients with a PHQ-9 score of 10 or higher should be evaluated for clinical depression and comorbid psychiatric conditions by either a primary care or mental health clinician (eg, psychologist or psychiatrist) before initiating treatment.
• The presence of suicidal ideation (item 9) should prompt a thorough self-harm assessment; several follow-up questions are suggested (eg, the P4 suicidality screener). 
